{"disease":{"id":"c3-glomerulopathy-c3g","name":"c3 glomerulopathy c3g"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05067127","title":"Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03301467","title":"Controlled Trial Evaluating Avacopan in C3 Glomerulopathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05222412","title":"Managed Access Programs for LNP023, Iptacopan","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04729062","title":"C3G/Primary IC-MPGN EAP","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}